Migraine is prevalent in Kuwait and is associated with significant burdens. Calcitonin gene-related peptide (CGRP) monoclonal antibodies were approved as preventive treatment for episodic and chronic migraine.

Migraine patients were identified in a tertiary center in Kuwait. The study included patients who received CGRP monoclonal antibodies. Patients were followed up every 4 weeks for at least 3 months. Primary end point was a 50% or greater reduction in migraine days. Secondary end points were change in the number of migraine days, number of days of use of analgesics, severity of headache pain, and change in Quality of life. Safety and tolerability were reported. Paired sample t test and Chi-square test were used to compare between different values.

This prospective study included 63 migraine patients, with a mean age of 44.59 years, disease duration of 21.87 years and treatment duration of 7.57 months. In their last visit, most of our sample showed improvement in quality of life (81%). Females represented 77.8% of the cohort. 57.2% of cohort used two or more previous prophylactic medication. 63.5% shifted to CGRP monoclonal antibodies because of lack of efficacy of previous medications and 20.6% because of adverse events. A 50% or greater reduction in the number of migraine days was achieved in 68.3% of patients. Patients had a significant reduction in migraine days, number of days of analgesic-usage and the severity of headache. Quality of life improved significantly. 14.4% reported adverse events. The most frequent ones were injection-site pain 6.4%, and constipation 6.4%. No Serious adverse events were reported.

Prophylactic CGRP monoclonal antibodies prevention of migraine were efficacious and reduced the number of monthly migraine days and the use of days of analgesics. It improved quality of life. It was tolerable and safe.